CytomX Therapeutics
Logotype for CytomX Therapeutics Inc

CytomX Therapeutics (CTMX) investor relations material

CytomX Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for CytomX Therapeutics Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

Platform and partnerships

  • PROBODY protease-cleavable masks localize potent biologic activity to tumor tissue; platform spans oncology modalities, with potential longer-term applications beyond oncology.

  • Lead clinical programs are Varseta-M, an EpCAM ADC for late-line colorectal cancer, and masked interferon alpha-2b for post-checkpoint inhibitor melanoma.

  • Regeneron alliance expanded midyear, with a new milestone announced the night before the conference; partnering advances candidates and generates capital.

Varseta-M efficacy and safety

  • In fourth-line-or-later CRC, ORR was 20%-30% at 8.6 and 10 mg/kg Q3W; available late-line options have response rates of 1%-2%.

  • PFS was 6-7 months in patients previously treated with irinotecan, supporting activity of the Topo1 ADC in the post-irinotecan setting.

  • No pancreatic signal or pancreatic enzyme modulation observed; hematologic toxicity rates were low for a Topo1 ADC.

  • Grade 3 diarrhea was ~30% at higher doses; upfront loperamide and budesonide reduced it to 10% after two months versus 29% in time-matched earlier cohorts; target is below 20%.

  • Optimization cohorts mandate both prophylactic drugs and use adjusted ideal body weight dosing to limit overexposure, particularly in patients with high BMI.

Data update and pivotal plans

  • Phase I enrollment totals 113 patients: 73 in escalation/expansion and 40 in optimization, split between 8.6 and 10 mg/kg Q3W cohorts.

  • January update planned across the study: longer follow-up, PFS and first OS data for the initial 73 patients, plus ORR and PFS for each 20-patient optimization cohort.

  • A randomized study of several hundred patients is anticipated, with upfront prophylaxis and OS as the primary endpoint; pivotal launch targeted for H1 next year.

  • Pivotal options are fourth-line-or-later versus physician's choice regorafenib or fruquintinib, or third-line versus bevacizumab plus LONSURF; January data and FDA feedback will inform the plan.

  • Fourth-line market potential estimated at $1 billion; total phase I efficacy and exposure-safety data will guide trial design and dose selection.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next CytomX Therapeutics earnings date

Logotype for CytomX Therapeutics Inc
Q4 202611 Mar, 2027
CytomX Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next CytomX Therapeutics earnings date

Logotype for CytomX Therapeutics Inc
Q4 202611 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. The company utilizes its proprietary Probody® platform to create antibody-based therapies that target cancer cells while minimizing damage to healthy tissues. CytomX’s approach aims to improve the safety and effectiveness of existing cancer therapies by activating its drugs only in the tumor microenvironment. The company's development pipeline includes therapeutic candidates designed for a variety of cancers, with the goal of addressing unmet medical needs in oncology. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.